1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

Express Scripts Value-Based Program To Leverage Generic Advair

 
• By Cathy Kelly

Pharmacy benefit manager Express Scripts plans to shake up the asthma/pulmonary and multiple sclerosis categories in 2018 with new contracting programs.

CrackedEggs_1200x675

Pharmacy benefit manager Express Scripts Holding Co. will roll out a value-based purchasing program in 2018 in the pulmonary drug category that will leverage the competition offered by an expected generic version of GlaxoSmithKline PLC's Advair Diskus (fluticasone/salmeterol) to lower costs.

"Our clients are clamoring from some reprieve from Advair in asthma, pulmonary conditions. So that will be the cornerstone of...

Welcome to Pink Sheet

Create an account to read this article

Already a subscriber?

More from Pricing Debate

Part B Negotiation Proposal Would Lower Prices In MA, Private Plans Too, Stakeholders Complain

 
• By Cathy Kelly

The issue is attracting more attention as the 2028 deadline for implementing Medicare negotiated prices for Part B drugs approaches.

Here At Last: Canada’s Long-Contested Guidelines For Curbing Excessive Drug Prices

 
• By Neena Brizmohun

Final guidelines explaining how staff at Canada’s Patented Medicine Prices Review Board should go about identifying drugs that could be considered for an excessive price hearing will come into force soon.

US Budget Bill Eases IRA Price Controls But Coverage Losses Will Impact Pharma

 
• By Cathy Kelly

The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 
• By Sarah Karlin-Smith

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

More from Market Access

‘Unprecedented Story’: Revoked EU Marketing Authorization Fails To Thwart Translarna Sales

 
• By Francesca Bruce

PTC Therapeutics is continuing to supply its Duchenne muscular dystrophy treatment, Translarna, in some European markets, despite EU revocation of the drug’s conditional marketing authorization earlier this year.

UK’s Plan To Become World’s Third Top Life Sciences Economy Falls Short, Says ABPI

 
• By Neena Brizmohun

The Association of the British Pharmaceutical Industry says that while the government’s newly published Life Sciences Sector Plan includes many positive commitments, they are not enough.

Spain’s Medicines Shortages Plan Clears Administrative Hurdles For Essential Medicine Manufacturers

 
• By Francesca Bruce

A new plan to tackle medicine shortages proposes to develop a set of incentives for companies to manufacture essential medicines in Spain.